Literature DB >> 24046438

Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool.

Yingda Xu1, William Roach, Tingwan Sun, Tushar Jain, Bianka Prinz, Ta-Yi Yu, Joshua Torrey, Jerry Thomas, Piotr Bobrowicz, Maximiliano Vásquez, K Dane Wittrup, Eric Krauland.   

Abstract

Low expression, poor solubility, and polyspecificity are significant obstacles that have impeded the development of antibodies discovered from in vitro display libraries. Current biophysical characterization tools that identify these 'developability' problems are typically only applied after the discovery process, and thus limited to perhaps a few hundred candidates. We report a flow cytometric assay using a polyspecificity reagent (PSR) that allows for the identification and counter selection of polyspecific antibodies both during and after the selection process. The reported assay correlates well with cross-interaction chromatography, a surrogate for antibody solubility, as well as a baculovirus particle enzyme-linked immunosorbent assay, a surrogate for in vivo clearance. However, unlike these assays, PSR labeling is compatible both with screening of individual antibodies as well as selections of large antibody libraries. To this end, we demonstrate the ability to counter-select against polyspecificity while enriching for antigen affinity from a diverse antibody library, which enables simultaneous evolution of both antigen binding and superior non-target-related properties during the discovery process.

Entities:  

Keywords:  antibody; cross interaction chromatography; directed evolution; flow cytometry; polyspecificity

Mesh:

Substances:

Year:  2013        PMID: 24046438     DOI: 10.1093/protein/gzt047

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  66 in total

1.  Arginine mutations in antibody complementarity-determining regions display context-dependent affinity/specificity trade-offs.

Authors:  Kathryn E Tiller; Lijuan Li; Sandeep Kumar; Mark C Julian; Shekhar Garde; Peter M Tessier
Journal:  J Biol Chem       Date:  2017-08-04       Impact factor: 5.157

2.  Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.

Authors:  Anna Z Wec; Zachary A Bornholdt; Shihua He; Andrew S Herbert; Eileen Goodwin; Ariel S Wirchnianski; Bronwyn M Gunn; Zirui Zhang; Wenjun Zhu; Guodong Liu; Dafna M Abelson; Crystal L Moyer; Rohit K Jangra; Rebekah M James; Russell R Bakken; Natasha Bohorova; Ognian Bohorov; Do H Kim; Michael H Pauly; Jesus Velasco; Robert H Bortz; Kevin J Whaley; Tracey Goldstein; Simon J Anthony; Galit Alter; Laura M Walker; John M Dye; Larry Zeitlin; Xiangguo Qiu; Kartik Chandran
Journal:  Cell Host Microbe       Date:  2019-01-09       Impact factor: 21.023

3.  Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.

Authors:  Zachary A Bornholdt; Hannah L Turner; Charles D Murin; Wen Li; Devin Sok; Colby A Souders; Ashley E Piper; Arthur Goff; Joshua D Shamblin; Suzanne E Wollen; Thomas R Sprague; Marnie L Fusco; Kathleen B J Pommert; Lisa A Cavacini; Heidi L Smith; Mark Klempner; Keith A Reimann; Eric Krauland; Tillman U Gerngross; Karl D Wittrup; Erica Ollmann Saphire; Dennis R Burton; Pamela J Glass; Andrew B Ward; Laura M Walker
Journal:  Science       Date:  2016-02-18       Impact factor: 47.728

4.  Reduction of Nonspecificity Motifs in Synthetic Antibody Libraries.

Authors:  Ryan L Kelly; Doris Le; Jessie Zhao; K Dane Wittrup
Journal:  J Mol Biol       Date:  2017-11-26       Impact factor: 5.469

Review 5.  Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire.

Authors:  Yariv Wine; Andrew P Horton; Gregory C Ippolito; George Georgiou
Journal:  Curr Opin Immunol       Date:  2015-07-10       Impact factor: 7.486

Review 6.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

7.  Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients.

Authors:  Beth Sharkey; Sarat Pudi; Ian Wallace Moyer; Lihui Zhong; Bianka Prinz; Hemanta Baruah; Heather Lynaugh; Sampath Kumar; K Dane Wittrup; Juergen H Nett
Journal:  MAbs       Date:  2016-12-12       Impact factor: 5.857

Review 8.  Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.

Authors:  Miroslav Dostalek; Thomayant Prueksaritanont; Robert F Kelley
Journal:  MAbs       Date:  2017-05-02       Impact factor: 5.857

9.  Biophysical properties of the clinical-stage antibody landscape.

Authors:  Tushar Jain; Tingwan Sun; Stéphanie Durand; Amy Hall; Nga Rewa Houston; Juergen H Nett; Beth Sharkey; Beata Bobrowicz; Isabelle Caffry; Yao Yu; Yuan Cao; Heather Lynaugh; Michael Brown; Hemanta Baruah; Laura T Gray; Eric M Krauland; Yingda Xu; Maximiliano Vásquez; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

10.  Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA.

Authors:  Juan Carlos Almagro; Gary L Gilliland; Felix Breden; Jamie K Scott; Devin Sok; Matthias Pauthner; Janice M Reichert; Gustavo Helguera; Raiees Andrabi; Robert Mabry; Mathieu Bléry; James E Voss; Juha Laurén; Lubna Abuqayyas; Stefan Barghorn; Eshel Ben-Jacob; James E Crowe; James S Huston; Stephen Albert Johnston; Eric Krauland; Fridtjof Lund-Johansen; Wayne A Marasco; Paul W H I Parren; Kai Y Xu
Journal:  MAbs       Date:  2014-03-03       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.